CFP

:   culture filtrate proteins

CW
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In United States, the tuberculosis (TB) rate has been decreasing since 1992, having a reported rate of three cases per 100 000 population in 2014 [1](#pmic12272-bib-0001){ref-type="ref"}. However, this country began to experience a severe interruption in the supply of isoniazid (INH) in 2012 [2](#pmic12272-bib-0002){ref-type="ref"}. INH is one of the most effective drugs to treat TB and to prevent active TB in persons with latent TB infection [3](#pmic12272-bib-0003){ref-type="ref"}, [4](#pmic12272-bib-0004){ref-type="ref"}. The INH scarcity affected the US TB programs and created incomplete treatment regimens that may lead to higher INH resistance rates over time.

Despite the proven success of INH against *Mycobacterium tuberculosis* (*Mtb*, the causing agent of TB), the understanding of its mechanism of action and development of resistance has been a slow process. INH is a prodrug that needs the bacterial enzyme KatG *(catalase‐peroxidase)* to become active. Activated INH inhibits mycolic acids biosynthesis, cell division, nucleic acid synthesis and electron transport, among other bacterial processes [5](#pmic12272-bib-0005){ref-type="ref"}, [6](#pmic12272-bib-0006){ref-type="ref"}. INH resistance mechanisms include mutations in multiple genes, most often in the *katG* gene.

Simultaneous to INH resistance development, *Mtb* can undergo further variations including changes in protein levels which in turn may counteract the potential fitness loss due to the new phenotype. A previous proteomic analysis compared INH susceptible (INHs) and resistant (INHr) strains of *Mtb* and found five proteins overexpressed in the INHr strains. These proteins were not related to any of the known INH resistance mechanisms [7](#pmic12272-bib-0007){ref-type="ref"}.

In the present study, we worked with clinical isogenic pairs of *Mtb*, to evaluate the variation in the protein levels after development of INH resistance. Clinical isogenic pairs are strains with the same genotype which can be obtained from the same patient before and after treatment. Although rare, isogenic pairs provide a unique setting to study drug resistance mechanisms and potential loss in fitness due to mutations conferring drug resistance without confounding effects due to intrinsic genotype differences.

We compared the global protein abundance levels of a clinical isogenic pair of *Mtb* and classified the proteome changes according with their functional category. Two isogenic strains of *Mtb* were isolated from a HIV positive patient, alcoholic, and intravenous drug user diagnosed in 1994 with pulmonary TB at University General Hospital of Gran Canaria Doctor Negrín, Las Palmas, Spain. The isolate obtained after drug treatment failure, was INHr to both concentrations tested (0.2 and 1.0 μg/mL). Both strains belong to the Beijing genotype, tested by restriction fragment length polymorphism RFLP ‐IS6110 [8](#pmic12272-bib-0008){ref-type="ref"} and spoligotyping [9](#pmic12272-bib-0009){ref-type="ref"}. Drug susceptibility profiles were confirmed for both strains using the agar proportion method [10](#pmic12272-bib-0010){ref-type="ref"} by National Jewish Hospital, Denver, CO. After INHr, the strain developed MDR (multidrug‐resistance) phenotype (resistance to i and rifampicin) and was successfully treated with second line drugs.

Bacteria culture condition, Culture Filtrate Protein (CFP) preparation, subcellular fractionation and proteomic analysis were performed as previously described with minor modifications [11](#pmic12272-bib-0011){ref-type="ref"}. Briefly, three biological replicates of each strain were cultured in one liter Glycerol‐Alanine‐salts media. The preparation of CFP and cell fractions required an initial filtration step (using a 0.2μm filter) and γ irradiation, respectively. Bacterial death was confirmed using the Alamar Blue assay (Invitrogen). CFP groups the secreted proteins and also those released onto the media during bacteria lysis. Cellular fractions include the mycobacterial membrane (MEM), cytosol (CYT) and cell wall (CW).

CFP was concentrated to a final volume of approximately 20 mL using a Millipore™ Amicon™ Bioseparations Stirred Cell with a 3‐KDa mass cutoff membrane (Millipore). Concentrated CFP and CYT fraction were subjected to buffer exchange with 10 mM ammonium bicarbonate, using Amicon Ultra‐15 centrifugal filter units with a 3‐kDa molecular mass cutoff. The CW and MEM pellets were resuspended in 10 mM ammonium bicarbonate.

After the separation of CFP and mycobacterial cell fractions, protein was quantified by the bicinchoninic acid method (Thermo Scientific™Pierce™). 30 μg of MEM, CYT and CFP were subjected to acetone precipitation, solubilization, reduction with dithiothreitol, alkylation with iodoacetamide, and trypsin digestion (using a mix of 1% ProteaseMaxTM Surfactant (Promega) and trypsin (Roche)) as described previously [11](#pmic12272-bib-0011){ref-type="ref"}. Following digestion, samples were desalted with Pierce® PepClean C18 columns (ThermoScientific) following the manufacturer instructions. CW proteins had a delipidation process [11](#pmic12272-bib-0011){ref-type="ref"} before to the protein digestion protocol described above.

One microgram of digested cellular fractions and CFP for all the three biological replicates were randomly analyzed in triplicate using LC‐MS/MS as described previously [11](#pmic12272-bib-0011){ref-type="ref"}. Resulting raw data were converted into mzXML files using ProteoWizard [12](#pmic12272-bib-0012){ref-type="ref"}. LC‐MS/MS spectra were then compared against *Mtb* genomic database (MtbReverse041712) using SORCERER (Sage‐N Research, version 5.0.1). The parameters used for the analysis were: trypsin digestion, a maximum of two missed cleavages, a precursor mass range of 400 to 4500 amu, peptide mass tolerance of 1.5 amu, reduction and alkylation of cysteine residues (resulting in the addition of a carbamidomethyl group, 15.99 amu) and the oxidation of methionine (57.02 amu).

For each cellular fraction, peptide identifications from the MS/MS spectra previously searched were combined in the proteomic software Scaffold (version Scaffold 4.3.2, Proteome Software Inc., Portland, OR) summing all the technical replicates results for each biological sample. Normalized spectral abundance factor (NSAF) analysis was performed to measure the relative protein abundance [13](#pmic12272-bib-0013){ref-type="ref"}. Additional parameters required for the Scaffold algorithm for protein identification included a maximum of 5% of false discovery rate for peptide threshold as well as for protein threshold and at least of two peptides.

The MS proteomics data have been deposited to the ProteomeXchange Consortium [14](#pmic12272-bib-0014){ref-type="ref"} via the PRIDE partner repository with the dataset identifier PXD002986 and 10.6019/PXD002986. Differences between protein abundances among the two different susceptibility profiles were tested by two tailed Student\'s *t*‐test.

We found 46 proteins either more or less abundant after acquisition of INHr (with *p* \< 0.05) that were grouped in seven different categories (Fig. [1](#pmic12272-fig-0001){ref-type="fig"}). These protein differences were mostly observed in the CFP (39.6%) and MEM (35.4%) fractions (Fig. [1](#pmic12272-fig-0001){ref-type="fig"}, Table [1](#pmic12272-tbl-0001){ref-type="table-wrap"}).

![Functional categories of the *Mtb* proteins showing different levels among the INHs and INHr isogenic strains (*p* value \<0.05). All categories are listed according to Tuberculist (version 2.6, Release 27 ‐ March 2013, <http://tuberculist.epfl.ch/>).](PMIC-16-1376-g001){#pmic12272-fig-0001}

###### 

Description of significantly different proteins in the INHr vs INHs Beijing strain comparison (*t*‐test, *p* \< 0.05)

  Proteins significantly different (*t*‐test, *p* \< 0.05)                    Gene name   Rv number   Functional category   Fold change (INHs/ INHr)[a)](#pmic12272-tbl1-note-0001){ref-type="fn"}
  --------------------------------------------------------------------------- ----------- ----------- --------------------- ------------------------------------------------------------------------
  *CFP (n = 19)*                                                                                                            
  Iron‐regulated peptidyl‐prolyl‐cis‐trans‐isomerase A                        ppiA        Rv0009      IMR                   ***1.6***
  Chaperone protein DnaK                                                      dnaK        Rv0350      V                     0.5
  Succinyl‐CoA synthetase beta chain                                          sucC        Rv0951      IMR                   ***4.1***
  Succinyl‐CoA synthetase alpha chain                                         sucD        Rv0952      IMR                   ***3.9***
  Enoyl‐CoA hydratase EchA9                                                   echA9       Rv1071c     L                     ***1.8***
  6‐phosphogluconate dehydrogenase, decarboxylating Gnd2                      gnd2        Rv1122      IMR                   ***2.9***
  Integration host factor MihF                                                mihF        Rv1388      IP                    ***1.7***
  Transaldolase                                                               tal         Rv1448c     IMR                   0.5
  Catalase‐peroxidase‐peroxynitritase T KatG                                  katG        Rv1908c     V                     ***14***
  Conserved protein                                                           Rv2204c     Rv2204c     C                     0.5
  Trigger factor protein                                                      tig         Rv2462c     CW                    ***3.5***
  Conserved protein                                                           Rv2699c     Rv2699c     C                     ***3.9***
  Adenosylhomocysteinase                                                      sahH        Rv3248c     IMR                   0.4
  Thiosulfate sulfurtransferase                                               sseA        Rv3283      IMR                   ***3.6***
  3‐hydroxyacyl‐thioester dehydratase HtdY                                    htdY        Rv3389c     L                     ***3.9***
  10 kDa chaperonin (protein CPN10), MPT57                                    groES       Rv3418c     V                     0.8
  Conserved protein                                                            Rv3433c    Rv3433c     C                     0.2
  Conserved membrane protein                                                  Rv3587c     Rv3587c     CW                    0.6
  Secreted fibronectin‐binding protein antigen protein                         fbpD       Rv3803c     L                     0.4
  *CW (n = 6)*                                                                                                              
  3‐oxoacyl‐\[acyl‐carrier protein\] reductase FabG4                          fabG4       Rv0242c     L                     0.4
  Acetyl‐CoA acyltransferase FadA2                                            fadA2       Rv0243      L                     0.5
  Immunogenic protein MPT63                                                   mpt63       Rv1926c     CW                    ***2.9***
  ATP‐dependent clp protease proteolytic subunit 2                            clpP2       Rv2460c     IMR                   0.5
  Fatty‐acid synthase (FAS)                                                   fas         Rv2524c     L                     0.3
  Transcriptional regulator, crp/fnr‐family                                   crp         Rv3676      R                     0.1
  *CYT (n = 6)*                                                                                                             
  Two component system transcriptional regulator PrrA                         prrA        Rv0903c     R                     0.3
  5‐methyltetrahydropteroyltriglutamate‐homocysteine methyltransferase MetE   metE        Rv1133c     IMR                   ***5.2***
  Malate dehydrogenase                                                        mdh         Rv1240      IMR                   ***1.3***
  Phosphoglycerate kinase                                                     pgk         Rv1437      IMR                   ***1.8***
  Catalase‐peroxidase‐peroxynitritase T KatG                                  katG        Rv1908c     V                     ***61***
  Aminomethyltransferase                                                      gcvT        Rv2211c     IMR                   0.2
  *MEM (n = 17)*                                                                                                            
  3‐hydroxyacyl‐thioester dehydratase HdtX                                    htdX        Rv0241c     L                     0.09
  Transport protein SecE2                                                     secE2       Rv0379      CW                    ***1.3***
  Polyprenyl‐diphosphate synthase                                             grcC1       Rv0562      IMR                   ***INF*** [b)](#pmic12272-tbl1-note-0002){ref-type="fn"}
  50S ribosomal protein L23, RplW                                             rplW        Rv0703      IP                    0.5
  Phosphoribosylformylglycinamidine synthase II                               purL        Rv0803      IMR                   ***1.7***
  Transcription termination factor Rho                                         rho        Rv1297      IP                    ***1.9***
  Thioredoxin                                                                 Rv1324      Rv1324      IMR                   ***3.2***
  Iron‐regulated aconitate hydratase                                          acn         Rv1475c     IMR                   ***1.3***
  Glycine dehydrogenase                                                       gcvB        Rv1832      IMR                   ***3.6***
  Catalase‐peroxidase‐peroxynitritase T KatG                                  katG        Rv1908c     V                     ***2.6***
  Monophosphatase                                                             cysQ        Rv2131c     IMR                   ***7.5***
  Pyruvate dehydrogenase E1 component                                         aceE        Rv2241      IMR                   ***1.2***
  Conserved protein                                                           Rv2402      Rv2402      C                     ***1.6***
  Chorismate synthase                                                         aroF        Rv2540c     IMR                   0.4
  Acyl‐CoA dehydrogenase FadE22                                               fadE22      Rv3061c     L                     0.5
  Acyl‐CoA dehydrogenase FadE32                                               fadE32      Rv3563      L                     0.1
  Enoyl‐CoA hydratase EchA21                                                  echA21      Rv3774      L                     ***2.7***

a\) The quantitative method chosen for the statistical analysis and *p* value calculation was NSAF.

b\) INF: NSAF in INHr strain was zero. IMR: Intermediary metabolism and respiration, V: Virulence, detoxification, adaptation, IP: Information pathways, L: Lipid metabolism, R: Regulatory protein, CW: Cell wall and cell wall processes, C: Conserved Hypothetical.

John Wiley & Sons, Ltd.

In our quantitative analysis, we particularly found low levels of KatG in the INHr isolate potentially explaining the resistance phenotype. The reduced levels of KatG were observed in all cellular fractions, except in the cell wall (Table [1](#pmic12272-tbl-0001){ref-type="table-wrap"}). In addition to the role of activating INH, KatG is also involved in the *Mtb* response to reactive oxygen intermediates produced by phagocytes during intracellular infections [15](#pmic12272-bib-0015){ref-type="ref"}, making this protein a well‐studied virulence factor.

The category "Intermediary metabolism and respiration (IMR)" presented the highest number of proteins (*n* = 20) with variable abundance among the strains. In this category the enzymes from the tricarboxylic acid (TCA) cycle SucC, SucD (located in the same operon), Mdh, Acn and AceE were all decreased in the INHr strain (Fig. [2](#pmic12272-fig-0002){ref-type="fig"}). AceE belongs to the aerobic oxidative TCA cycle. Additionally, two enzymes of the pentose phosphate pathway Gnd2 and Tal were also significantly different in this analysis but with higher and lower levels in the INHr strain, respectively (Table [1](#pmic12272-tbl-0001){ref-type="table-wrap"}).

![TCA cycle in *Mtb*. The enzymes in the boxes are reduced in the Beijing INHr strain. Adapted from <http://biocyc.org/MTBRV>.](PMIC-16-1376-g002){#pmic12272-fig-0002}

Among lipid metabolism, we detected differences in proteins involved in lipid biosynthesis and degradation pathways. For the former, FabG4 and Fas were increased in the INHr strain. FabG4 participates in the elongation of saturated fatty acids while Fas is a structurally integrated type I fatty acid synthase (FAS‐I), similar to those found in eukaryotes. This particular enzyme has all catalytic domains contained within a single protein chain [16](#pmic12272-bib-0016){ref-type="ref"}. There were also enzymes identified in this study that belong to the FAS‐II system, Rv0241 (HtdX) and Rv3389 (HtdY), but with different behavior. While HtdX had higher, HdtY had lower abundance levels in the INHr strain. Due to their sequence and structure, both enzymes are considered 3‐hydroxyacil thioester dehydratases, but HtdX has a particular high capacity to produce lipoic acid and an increased preference for its substrate (3‐hydroxyacyl‐acyl carrier protein, ACP) [17](#pmic12272-bib-0017){ref-type="ref"}. In our study, HdtX trend was similar to the other enzymes involved in lipid biosynthesis. The different levels observed between HtdX and HtdY may be in line with results elsewhere indicating that HdtY may not be part of the ACP‐dependent FAS‐II system [17](#pmic12272-bib-0017){ref-type="ref"}.

For fatty acid β oxidation, the dehydrogenases FadE22 and FadE32 and the acetyl‐CoA acyltransferase FadA2 were increased while the crotonases EchA9 and EchA21 were decreased in the INHr strain (Table [1](#pmic12272-tbl-0001){ref-type="table-wrap"}).

In summary, we demonstrated that acquisition of INH resistance can result in significant changes in the mycobacteria proteome, particularly in pathways related to respiration and lipid metabolism, both of which may result as a compensatory mechanism to the decrease in KatG abundance and its consequent impact on mycobacterial physiology and fitness.
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